Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round

NORWALK, Conn., Oct. 22, 2014 /PRNewswire/ -- Recently published clinical studies of Stretta for gastroesophageal reflux disease (GERD) have bolstered the already substantial database of evidence. This data has led to significantly expanded insurance coverage and adoption of Stretta therapy for sufferers of refractory GERD.

The substantial body of clinical evidence supporting Stretta therapy as a safe and effective GERD treatment has driven new coverage policies that make Stretta therapy available to nearly 50 million Americans. The new clinical studies include; a five-year follow up comparison of Stretta to Laparoscopic Nissen fundoplication; a five-year follow-up study of patients suffering from laryngopharyngeal reflux, also known as "silent reflux;" eight and ten-year Stretta follow-up studies; a cost effectiveness study comparing various treatments for GERD including Stretta, and a histologic examination of the effects of non-ablative radiofrequency energy on smooth muscle tissue.

Based on the data and the expanded coverage, Mederi is completing another round of financing in the form of convertible notes. These proceeds will be used to grow its domestic sales force and to advance the worldwide commercialization of Mederi's Stretta therapy for GERD and Secca therapy for Bowel Incontinence.

For more information go to: www.stretta-therapy.com

ABOUT MEDERI^®

Mederi Therapeutics Inc. manufactures and markets innovative medical devices that use radiofrequency energy to treat diseases of the digestive system. Mederi's minimally invasive therapies Stretta^® for GERD and Secca^® for Bowel Incontinence are performed on an outpatient basis, have demonstrated clinical effectiveness in numerous studies, and are available worldwide.

For media inquiries contact:
Julia Brannan
(908) 464-2470
[email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/recent-clinical-study-data-confirms-efficacy-of-stretta-therapy--spurs-additional-insurance-coverage-and-financing-round-775204722.html

SOURCE Mederi Therapeutics Inc.